Evolution of the Average Target: Sanofi

Data source: Sanofi(SAN)
Evolution of the Average Target - Sanofi

Evolution of the Target Price: Sanofi

Data source: Sanofi(SAN)
Evolution of the Target Price - Sanofi

Changes in Analyst Recommendations: Sanofi

Data source: Sanofi(SAN)
5a16044ea379e09d5fd8ed25.V9KdDGX7ILg--T_HtwWK98iOruQFEPXrQWC99DHbE74.FZD2SiapV8tam32Gj0PIsOXd6Yo3X6-MJzDcwFyReIgDnqRtApFN71jNbg~29f47acb0cd99c7352cc2eeb534791f1
11-13 Sanofi extends its winning streak, Citi raises target Zonebourse
11-09 Sanofi Shares Rise After Upgrade From BNP Paribas MT
11-09 BNP Paribas Upgrades Sanofi to Outperform From Neutral, Price Target is $57 MT
11-09 Sanofi : UBS gives a Neutral rating ZD
11-09 Sanofi in the spotlight, several analysts raise target prices Zonebourse
11-09 Sanofi in the spotlight, several analysts raise their price targets Zonebourse
11-06 Sanofi : Deutsche Bank maintains a Buy rating ZD
11-06 AlphaValue/Baader Europe Lifts Sanofi Price Target Amid Continued Dupixent Strength MT
11-06 Sanofi: Unrelenting Dupixent prompts an upgrade Alphavalue
11-05 AlphaValue/Baader Europe Upgrades Sanofi to Add MT
11-04 Sanofi Maintained at Buy as Berenberg Notes R&D Transformation MT
11-04 Sanofi : DZ Bank gives a Buy rating ZD
11-04 Sanofi : Bernstein remains its Buy rating ZD
11-04 Sanofi : Gets a Buy rating from Berenberg ZD
11-04 Sanofi : JP Morgan reiterates its Neutral rating ZD
11-02 Sanofi : RBC is Neutral ZD
11-02 Regeneron's 'Strong Commercial' Q3 Underscores Core Business Health, RBC Capital Markets Says MT
11-02 RBC Raises Price Target on Sanofi to EUR80 From EUR75, Keeps Sector Perform Rating MT
11-02 Sanofi : Barclays reiterates its Neutral rating ZD
11-02 Sanofi : Receives a Buy rating from Deutsche Bank ZD
11-02 Sanofi : Gets a Buy rating from Jefferies ZD
11-02 French and Benelux stocks-Factors to watch on November 2 RE
11-02 Sanofi : RBC is Neutral ZD
10-30 Sanofi: Impressive Q3 beat; depressed valuation limits downside risks Alphavalue
10-30 Sanofi : Jefferies keeps its Buy rating ZD

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+1.38%
-2.22%
+5.69%
-2.05%
+9.32%
-3.71%
+16.57%
-7.27%
+3.98%
Average +2.41%
Weighted average by Cap. +1.97%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
87.60EUR
Average target price
96.36EUR
Spread / Average Target
+10.00%
High Price Target
110.00EUR
Spread / Highest target
+25.57%
Low Price Target
79.00EUR
Spread / Lowest Target
-9.82%

Analyst Consensus Detail

Analyst consensus - Sanofi

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Sanofi
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Sanofi